Key Points Pembrolizumab was first shown to be clinically active in CLL patients with RT. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select RT patients for PD-1 blockade.
Comparative analysis of de novo assemblers for variation discovery in personal genomes
Briefings in Bioinformatics | March 16, 2017 | Volume: 19 | Issue: 5 | Pages: 893-904